Stay updated with breaking news from Heather fehling. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
20 to Know: These innovators help keep Kansas City on the leading edge - Kansas City Business Journal bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.
NA Proactive news snapshot: Zynerba Pharmaceuticals, Nerds On Site, Marvel Discovery, Water Tower Research UPDATE … A glance at some of the day s highlights from the Proactive Investors US and Canada newswires Your daily round-up from the world of Proactive Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting two posters at the Society of Biological Psychiatry (SOBP) 2021 Virtual Meeting. The first poster is titled, “Cannabidiol in Fragile X Syndrome (FXS): Proposed Mechanism of Action (MOA) Translates Into Meaningful Clinical Benefits [CONNECT-FX (ZYN2-CL-016)]. The second poster is titled, “A Pivotal Study of ZYN002 Cannabidiol (CBD) Transdermal Gel in Children and Adolescents With Fragile X Syndrome [CONNECT-FX (ZYN2-CL-016)].” ....
NA Proactive news snapshot: Zynerba Pharmaceuticals, Nerds On Site, Marvel Discovery, Water Tower Research UPDATE … A glance at some of the day s highlights from the Proactive Investors US and Canada newswires Your daily round-up from the world of Proactive Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting two posters at the Society of Biological Psychiatry (SOBP) 2021 Virtual Meeting. The first poster is titled, “Cannabidiol in Fragile X Syndrome (FXS): Proposed Mechanism of Action (MOA) Translates Into Meaningful Clinical Benefits [CONNECT-FX (ZYN2-CL-016)]. The second poster is titled, “A Pivotal Study of ZYN002 Cannabidiol (CBD) Transdermal Gel in Children and Adolescents With Fragile X Syndrome [CONNECT-FX (ZYN2-CL-016)].” ....
NA Proactive news snapshot: Zynerba Pharmaceuticals, Nerds On Site, Marvel Discovery, Water Tower Research UPDATE … A glance at some of the day s highlights from the Proactive Investors US and Canada newswires Your daily round-up from the world of Proactive Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting two posters at the Society of Biological Psychiatry (SOBP) 2021 Virtual Meeting. The first poster is titled, “Cannabidiol in Fragile X Syndrome (FXS): Proposed Mechanism of Action (MOA) Translates Into Meaningful Clinical Benefits [CONNECT-FX (ZYN2-CL-016)]. The second poster is titled, “A Pivotal Study of ZYN002 Cannabidiol (CBD) Transdermal Gel in Children and Adolescents With Fragile X Syndrome [CONNECT-FX (ZYN2-CL-016)].” ....
Share this article SALT LAKE CITY, April 29, 2021 /PRNewswire/ Co-Diagnostics, Inc. (Nasdaq: CODX) (the Company ), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that it will be accompanying Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Lab ( CRL ) in a webinar titled A New Generation of PCR: At-home Testing and Preparing for Emerging Strains of COVID-19 on Thursday, April 29 at 2:00 PM EDT. The 360Dx webinar is expected to provide insights regarding future applications of PCR testing for COVID-19, how CRL is able to provide non-invasive and highly accurate saliva PCR tests for at-home collection, and how new PCR science and technology is enabling and expanding the applications and accessibility of PCR tests. Co-Diagnostics Senior Design Engineer Masen Christensen will discuss the results of ongoing monitoring and analyses of emerging COVID-19 mutations as they relat ....